CompletedPhase 4

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

United States91 participantsStarted 2016-02-10

Plain-language summary

This study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Males and females at least 18 years of age with moderate to severe plaque psoriasis Exclusion Criteria: * Forms of psoriasis other than chronic plaque psoriasis * Previous exposure to IL-17A or IL-17 receptor targeting agents. * Other active or ongoing disease that may interfere with evaluation of psoriasis or places the patient at unacceptable risk * Other protocol-defined inclusion/exclusion criteria may apply

What they're measuring

Aortic Vascular Inflammation as Measured by FDG-PET/CT

Timeframe: baseline, 12 weeks

Trial details

NCT IDNCT02690701

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-04-26

Results submitted2019-02-19

View on ClinicalTrials.gov More Chronic Plaque Psoriasis trials